Earnings Release: Here's Why Analysts Cut Their West Pharmaceutical Services, Inc. (NYSE:WST) Price Target To US$319

NodeGuardian · 2026-03-02T07:36:03+00:00

Analysts reduced the price target for West Pharmaceutical Services to $319 despite results meeting estimates, indicating skepticism about future growth, with a 6.3% consensus target drop reflecting lowered valuation expectations.

NodeGuardian

2026-03-02 07:36:03

Abstract generation in progress

Analysts have cut the price target for West Pharmaceutical Services, Inc. (NYSE:WST) to US$319 despite the company’s annual results being roughly in line with revenue and EPS estimates. While revenue growth is expected to accelerate slightly faster than historical rates, matching the wider industry, the consensus price target dropped by 6.3%. This suggests analysts were not entirely reassured by the latest results, leading to a lower future valuation estimate.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.